Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

Drug development contract services company PPD announces initial public offering. 

PPD Launches IPO

FDA revised the guidance after industry feedback and to clarify CGMP requirements for outsourcing facility operations.

FDA Revises Compounding Guidance

Karen Flynn rejoins Catalent as president of biologics operations; regional presidents named for US and Europe.  

Catalent Biologics Announces Senior Leadership Appointments

Catalent’s FlexDirect service offers sponsors multiple delivery options from a single inventory.

Catalent Launches Direct-to-Patient Clinical Supply Services

Phillips-Medisize has announced  that it is expanding its current Global Innovation and Development (GID) site in Struer, Denmark, to include a dedicated manufacturing development and clinical build unit.


Phillips-Medisize Grows Clinical Manufacturing Capabilities to Meet Demand

Catalent completes purchase of biologics fill-finish and oral solid dose facility in Anagni, Italy

Catalent Expands Fill-Finish Capacity

Catalent’s planning service is designed to assist in evaluating needs for launching and maintaining clinical trials. 

Catalent Announces Clinical Trial Planning Service

The acquisition expands Charles River’s scientific capabilities in cell therapy development.

Charles River Laboratories to Acquire HemaCare in $380-Million Deal

Cambrex reports that the acquisition by the investment group will facilitate ongoing growth.

Cambrex Sale to Premira Funds Affiliate Closes

Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.
